Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial

医学 随机对照试验 他汀类 冠状动脉疾病 内科学 临床终点 冠状动脉钙 无症状的 风险因素 阿托伐他汀 队列 心脏病学 物理疗法
作者
P. Venkataraman,Quan Huynh,Stephen J. Nicholls,Tony Stanton,Gerald F. Watts,Thomas H. Marwick
出处
期刊:Atherosclerosis [Elsevier BV]
卷期号:334: 57-65 被引量:14
标识
DOI:10.1016/j.atherosclerosis.2021.08.002
摘要

Coronary artery calcium (CAC) may encourage patients to adhere to primary prevention recommendations. This study sought to evaluate the benefit of a CAC-guided risk-management protocol in those with a family history of premature coronary artery disease (FHCAD).In this Australian multi-centre, randomized controlled trial (Coronary Artery Calcium score: Use to Guide management of Hereditary Coronary Artery Disease, CAUGHT-CAD), asymptomatic, statin-native participants at low-intermediate cardiovascular risk with FHCAD underwent CAC assessment. Those with CAC between 1 and 400 were randomized (1:1) to disclosing the CAC result to both patient and physician and commencing atorvastatin (intervention) or blinding the CAC result with risk factor education only (control). The primary endpoint of this sub-study was change in Pooled Cohort Equation (PCE) at 12 months.Of 1088 participants who were scanned, 450 were randomised and 214 in both groups completed 1-year follow-up. At 1 year, PCE-risk decreased by 1.0% (95% CI 0.13 to 1.81) in the CAC-disclosed group and increased by 0.43% (95%CI 0.11-0.75) in the CAC-blinded group. LDL-C decreased in the CAC-disclosed group in both those who continued (1.5 mmol/L; 95% CI 1.36 to 1.74) and discontinued statins (0.62 mmol/L; 95% CI 0.32 to 0.92) but was unchanged in the CAC-blinded group.Participants unblinded to their CAC showed reductions in LDL irrespective of statin continuation when compared to controls at 12 months. Improvements in individual risk factors and PCE risk were also noted. CAC assessment may positively influence patients and physicians to improve risk factor control.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包的应助被嘻嘻采纳,获得10
1秒前
1秒前
1秒前
斯文败类的应助被Aboo采纳,获得10
1秒前
沫沫发布了新的文献求助10
2秒前
2秒前
muyi完成签到,获得积分10
2秒前
3秒前
3秒前
cqzhang完成签到,获得积分10
3秒前
4秒前
明明完成签到,获得积分10
4秒前
深情安青的应助被三白采纳,获得10
4秒前
科研通AI65的应助被ben采纳,获得10
5秒前
科研通AI65的应助被Code_king采纳,获得10
5秒前
syvshc的应助被Code_king采纳,获得10
5秒前
寂寞的小鱼的应助被Code_king采纳,获得10
6秒前
6秒前
8秒前
000000发布了新的文献求助10
9秒前
一百八完成签到,获得积分10
10秒前
11秒前
柔弱的笑蓝完成签到,获得积分10
12秒前
斯文败类的应助被cyu采纳,获得10
12秒前
刘宁完成签到 ,获得积分10
12秒前
yyy关注了科研通微信公众号
13秒前
顺心卿发布了新的文献求助10
14秒前
14秒前
15秒前
落单的情绪完成签到 ,获得积分10
16秒前
17秒前
南方三炁火德星君完成签到,获得积分10
17秒前
17秒前
18秒前
甜蜜的依玉完成签到,获得积分10
18秒前
19秒前
19秒前
李健的应助被白羽采纳,获得10
19秒前
万能图书馆的应助被洗衣机采纳,获得10
19秒前
我是老大的应助被小张医生采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177654
求助须知:如何正确求助?哪些是违规求助? 9568503
关于积分的说明 21799551
捐赠科研通 7772253
什么是DOI,文献DOI怎么找? 3432428
关于科研通互助平台的介绍 2556594
邀请新用户注册赠送积分活动 2478011